Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  dacarbazine
Find trials that include:  Any drugs shown
Results 1-8 of 8 for your search:
Start Over
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PV-10-MM-31, NCI-2015-00568, NCT02288897
Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHP-OCM-301, NCI-2016-00242, NCT02678572
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with Stage II-IV HIV-Associated Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-085, NCI-2013-00046, 085, 2014-003678-18, NCT01771107
Response-Based Therapy Assessed by PET Scan in Treating Patients with Stage IA-IIB Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 to 60
Trial IDs: CALGB-50801, NCI-2011-02034, CDR0000669076, NCT01118026
Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients with Stage IIB-IVB Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and under
Trial IDs: HLHR13, NCI-2013-01123, NCT01920932
Brentuximab Vedotin, Doxorubicin Hydrochloride, and Dacarbazine in Treating Patients with Previously Untreated Stage I-IIB Non-bulky Classical Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-196, NCI-2015-01592, 35-IST-029, NCT02505269
Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Patients with Newly Diagnosed, Early Stage, Unfavorable-Risk Hodgkin Lymphoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 to 60
Trial IDs: 13-034, NCI-2013-01144, NCT01868451
Start Over